Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population

Tandem anaerobic-aerobic degradation of ranitidine, diclofenac, and simvastatin in domestic sewage

There is a consensus among scientists that domestic sewage treatment plants are the main sources of drugs entry into the aquatic environment. Therefore, this work studies the biodegradation of the drugs ranitidine (RNT), diclofenac (DCF), and simvastatin (SVT) (50 μg L^-1, each), in real domestic sewage, using a continuous anaerobic-aerobic reactor with immobilized biomass and an anaerobic batch reactor. The continuous anaerobic-aerobic reactor was operated for 6 months with hydraulic retention time (HRT) of 8 h. The initial degradation rates and the maximum oxidation capacities (MOC) of the system were estimated, achieving 90, 72, and 62% removals and 100, 93, and 72% of MOC for RNT, DCF and SVT, respectively, as well as 71% removal of soluble chemical oxygen demand (COD). RNT was degraded throughout the reactor, while DCF was degraded mainly in the two anaerobic chambers and SVT in the first anaerobic chamber. Anaerobic batches were used for the identification of biodegradation by-products (2,6-dichloro-N-(2-methylphenyl) aniline and simvastatin acid), the evaluation of the specific methanogenic activity (SMA) inhibition, and the estimation of acute and chronic ecotoxicities using the ECOSAR 1.11 software. The present study showed that, even at environmental concentrations, RNT, DCF, and SVT were capable of inhibiting the SMA. Lipophilicities dictated the behavior of those three drugs. The greater their lipophilicities, the greater the SMA inhibition and their ecotoxicity.

Cetyl-alcohol-reinforced hollow fiber solid/liquid-phase microextraction and HPLC-DAD analysis of ezetimibe and simvastatin in human plasma and urine

A new cetyl-alcohol-reinforced hollow fiber solid/liquid-phase microextraction (CA-HF-SLPME) followed by high-performance liquid chromatography-diode array detection (HPLC-DAD) method was developed for simultaneous determination of ezetimibe and simvastatin in human plasma and urine samples. To prepare the CA-HF-SLPME device, the cetyl-alcohol was immobilized into the pores of a 2.5 cm hollow fiber micro-tube and the lumen of the micro-tube was filled with 1-octanol with the two ends sealed. Afterwards, the prepared device was introduced into 10 mL of the sample solution containing the analytes with agitation. Under optimized conditions, calibration curves plotted in spiked plasma and urine samples were linear in the ranges of 0.363-25/0.49-25 μg L^-1 for ezetimibe/simvastatin and 0.193-25/0.312-25 μg L^-1 for ezetimibe/simvastatin in plasma and urine samples, respectively. The limit of detection was 0.109/0.174 μg L^-1 for ezetimibe/simvastatin in plasma and 0.058/0.093 μg L^-1 for ezetimibe/simvastatin in urine. As a potential application, the proposed method was applied to determine the concentration of selected analytes in patient plasma and urine samples after medication and satisfactory results were achieved. In comparison with reference methods, the CA-HF-SLPME-HPLC-DAD method demonstrates considerable potential in the biopharmaceutical analysis of selected drugs.

Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine

The natural alkaloid berberine has been ascribed numerous health benefits including lipid and cholesterol reduction and improved insulin sensitivity in diabetics. However, oral (PO) administration of berberine is hindered by poor bioavailability and increasing dose often elicits gastro-intestinal side effects. To overcome the caveats associated with oral berberine, we developed transdermal (TD) formulations of berberine (BBR) and the berberine precursor dihydroberberine (DHB). These formulations were compared to oral BBR using pharmacokinetics, metabolism, and general safety studies in vivo. To complete this work, a sensitive quantitative LC-MS/MS method was developed and validated according the FDA guidelines for bioanalytical methods to simultaneously measure berberine, simvastatin, and simvastatin hydroxy acid with relative quantification used for the berberine metabolite demethylene berberine glucuronide (DBG). Acute pharmacokinetics in Sprague-Dawley rats demonstrated a statistically relevant ranking for berberine bioavailability based upon AUC_0-8 as DHB TD > BBR TD >> BBR PO with similar ranking for the metabolite DBG, indicating that transdermal administration achieves BBR levels well above oral administration. Similarly, chronic administration (14 days) resulted in significantly higher levels of circulating BBR and DBG in DHB TD treated animals. Chronically treated rats were given a single dose of simvastatin with no observed change in the drugs bioavailability compared with control, suggesting the increased presence of BBR had no effect on simvastatin metabolism. This observation was further supported by consistent CYP3A4 expression across all treatment groups. Moreover, no changes in kidney and liver biomarkers, including alanine aminotransferase and alkaline phosphatase, were observed between treatment formats, and confirming previous reports that BBR has no effect on HMG-CoA expression. This study supports the safe use of transdermal compositions that improve on the poor bioavailability of oral berberine and have the potential to be more efficacious in the treatment of dyslipidemia or hypercholesterolemia.